Inion promotes Christian Johnson to Sales Director
January 15 2009 - 6:17AM
RNS Non-Regulatory
TIDMIIN
Inion Oy
15 January 2009
?
Inion Oy
("Inion or the "Company")
Inion promotes Christian Johnson to Sales Director responsible for markets
outside the USA
Tampere, Finland and Guildford, UK. 15 January 2009, Inion (LSE: IIN.L), a
company focused on the development and commercialisation of novel biodegradable
medical implants, is pleased to announce the promotion of Christian Johnson to
the position of Sales Director for key markets outside the USA. He will report
to David Follows, Inion's Chief Operating Officer.
Christian is a sales and marketing professional with 11 years of experience
gained initially in the pharmaceutical industry and later in the medical devices
industry. Most recently, he spent seven successful years at Johnson & Johnson
working in a number of sales and marketing roles of increasing responsibility
within its Spine Implant Business Unit (part of J&J's DePuy operating company).
During this time, he gained valuable experience in launching and marketing
innovative new products, such as a pedicle screw system for spine fusion, which
quickly became DePuy's number one brand. Christian also demonstrated excellent
leadership qualities and recruited and developed a new team that contributed
significantly to the overall success of DePuy's UK business.
Since joining Inion in 2007, Christian has made a significant contribution
within the Marketing Team in supporting the refocus and prioritization of the
Company's portfolio of innovative biodegradable medical implants for spine and
speciality orthopaedic applications.
Chris Lee, Inion's CEO, said, "Christian's passion for Inion's product
portfolio, support of the aims and ambitions of our organisation and his desire
for success make him the ideal choice to take on this demanding role. Inion is
focused on establishing a well-organised and profitable international sales and
marketing operation and we are confident that Christian has the necessary
qualities to build this important part of our business. We congratulate him on
this well-deserved promotion."
-ends-
For further information, please contact:
Inion Oy
Chris Lee, Chief Executive Officer
Julien Cotta, Chief Financial Officer
Tel: +44 (0)1483 685390
Citigate Dewe Rogerson
Mark Swallow / Helena Galilee / David Dible
Tel: +44 (0)207 638 9571
About Inion (www.inion.com)
Inion Oy is a medical devices company focused on the development and successful
commercialisation of innovative and unique biodegradable and bioactive surgical
implants in selected high value orthopaedic market segments.
Inion's core expertise and technology lies in the design and manufacture of
innovative biodegradable plates, screws, pins and membranes, which are used to
enhance the healing of bone or soft tissue injuries to the skeleton, such as
those caused by trauma or by reconstructive surgery. Inion implants are made
from its proprietary Inion family of biomaterials, with properties tailored for
specific surgical applications, in terms of strength, flexibility and rate of
degradation
Inion is also focused on developing proprietary new bioactive and biodegradable
biomaterials that promote bone healing and accelerate patient rehabilitation.
Inion was incorporated in early 2000 and listed on the Official List of the UK
Listing Authority in December 2004 (ticker: IIN). The Company has offices in the
UK and US, and its head office, R&D and production facilities are in Tampere,
Finland.
This announcement includes "forward-looking statements" which include all
statements other than statements of historical facts, including, without
limitation, those regarding the Group's financial position, business strategy,
plans and objectives of management for future operations (including development
plans and objectives relating to the Group's products), and any statements
preceded by, followed by or that include forward-looking terminology such as the
words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions
or the negative thereof. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors beyond the Group's
control that could cause the actual results, performance or achievements of the
Group to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such
forward-looking statements are based on numerous assumptions regarding the
Group's present and future business strategies and the environment in which the
Group will operate in the future. Among the important factors that could cause
the Group's actual results, performance or achievements to differ materially
from those in forward-looking statements include those relating to Inion's
funding requirements, regulatory approvals, reliance on third parties,
intellectual property, key personnel and other factors. These forward-looking
statements speak only as at the date of this announcement. The Group expressly
disclaims any obligation or undertaking to disseminate any updates or revisions
to any forward-looking statements contained in this announcement to reflect any
change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result
of these factors, prospective investors are cautioned not to rely on any
forward-looking statement.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGUUAGGUPBGGA
Inion Oy (LSE:IIN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Inion Oy (LSE:IIN)
Historical Stock Chart
From Oct 2023 to Oct 2024